Welcome
Support Centre
07 August 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Corneal Collagen Cross-linking with Riboflavin (C3R) with orthokeratology
ISRCTN ISRCTN29378493
ClinicalTrials.gov identifier
Public title Corneal Collagen Cross-linking with Riboflavin (C3R) with orthokeratology
Scientific title Pilot study of corneal collagen cross-linking with riboflavin (C3R) with pre-operative orthokeratology
Acronym C3R
Serial number at source CHAR1004
Study hypothesis To assess whether orthokeratology using a specifically designed contact lens could enhance the corneal flattening effect of collagen cross-linking by ultraviolet (UV) light with riboflavin (C3R) and reduce any pre-existing astigmatism and/or myopia.
Ethics approval Ethics approval received from Moorfields and Whittington Hospitals Research Ethics Committee on the 1st December 2006 (ref: 06/Q0504/106).
Study design Pilot randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Corneal ectasia
Participants - inclusion criteria Corneal ectasia (keratoconus, pellucid marginal degeneration or post-excimer laser corneal ectasia) in patients intolerant or with limited tolerance of contact lenses. The only other options would be INTACS or corneal grafting.
Participants - exclusion criteria 1. Age less than 18 years or greater than 40 years
2. Maximal K greater than 60D
3. Minimal Oculus Pentacam pachymetry less than 400 u, to avoid the risk of endothelial damage
4. Evidence of other corneal disease in the eye to be treated (e.g., herpes simplex keratitis)
5. Women who are pregnant or nursing at the time of the initial treatment
6. Presence of significant central corneal opacity
7. Patients unwilling to not wear their rigid contact lenses in the eye to be treated for at least one month before baseline examination, and for the first six months post-operatively (this will be necessary in order to obtain accurate refraction and keratometry readings)
Anticipated start date 05/09/2007
Anticipated end date 05/09/2008
Status of trial Ongoing
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 20
Interventions Corneal collagen cross-linking with riboflavin and UV light, plus or minus orthokeratology.

Pre-operatively:
10 patients will be fitted with a specially-made contact lens, which they will need to wear for one week prior to the surgical procedure, in an attempt to change the irregular profile of the cornea prior to undergoing the corneal collagen cross-linking (C3R) treatment. The other 10 patients will not be fitted with any kind of lens.

Surgical procedure:
The surgery will be performed on all 20 patients. Local anaesthesia with anaesthetic eye drops will be utilised. The procedure involves removal of the superficial cell layer of the cornea (epithelium) and then instilling riboflavin eye drops into the eye every three minutes for 30 minutes, until the surgeon judges that an adequate level has been obtained. At that point the ultraviolet light will be directed onto the cornea for 30 minutes to produce collagen cross-linking. Cross-links are small bridges between the fibres in the cornea which strengthen the cornea. Total time for the procedure will be about 1 hour 15 minutes to 1 hour 30 minutes.
Primary outcome measure(s) The difference in the pre- and post-operative:
1. Unaided visual acuity
2. Best corrected visual acuity
3. Refraction
Secondary outcome measure(s) Corneal topographical profile, measured pre-operatively and at one and six months post-operatively.
Sources of funding Moorfield Eye Hospital Special Trustees (UK)
Trial website
Publications
Contact name Mr  Chad  Rostron
  Address Duke Elder Eye Unit (Moorfields Eye Department)
St George's Hospital
Blackshaw Road
  City/town London
  Zip/Postcode SW17 0QT
  Country United Kingdom
  Tel +44 (0)20 8725 2325
  Fax +44 (0)20 8725 3026
  Email rostron@sgul.ac.uk
Sponsor Moorfields Eye Hospital NHS Foundation Trust (UK)
  Address c/o Professor Roger Hitchings
162 City Road
  City/town London
  Zip/Postcode EC1V 2PD
  Country United Kingdom
  Sponsor website: http://www.moorfields.nhs.uk/Home
Date applied 14/02/2008
Last edited 27/03/2008
Date ISRCTN assigned 27/03/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central